La chaîne d'options affiche les données clés des options sur actions de Everbright Digital Hldgs à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Everbright Digital Hldgs..

Everbright Digital Hldgs (NASDAQ:EDHL) Stock, Chaîne d'Options

Everbright Digital Holding Ltd is an integrated marketing solutions provider in Hong Kong that is involved in the metaverse and related technologies, and is providing one-stop digital marketing services for the process of enterprise development. Its digital marketing solutions include metaverse stimulation, virtual reality (VR) and augmented reality (AR) design and creation, creative event planning and management, IP character creation and social media marketing.

Everbright Digital Holding Limited - Ordinary Shares

Everbright Digital Holding Ltd

Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). The company&nbsp;will announce second-quarter 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46095809/pfizer-invites-public-to-view-and-listen-to-webcast-of-august-5-conference-call-with-analysts" rel="noreferrer noopener">earnings on August 5</a>.
According to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, analysts estimate adjusted earnings of 57 cents per share on sales of $13.41 billion.
In the second quarter, total revenue decreased by less than 1%, and earnings per share remained unchanged.
Analysts also expect revenue and EPS to stay within 1% of previous forecasts. Revenue will likely decline by a low single-digit percentage in the latter part of the 2020s, they say. This is mainly due to Vyndaqel and Ibrance&#8217;s earlier-than-expected loss of exclusivity.
Read Next: <a href="https://www.benzinga.com/news/legal/25/07/46364944/pfizer-sanofi-find-relief-as-delaware-top-court-rejects-zantac-expert-testimony" target="_blank" rel="noreferrer noopener">Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony</a>
EPS is also expected to shift up or down by a low single-digit percentage, depending on the year.
BofA maintains the <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price forecast of $27</a> with a Neutral rating using a 9x P/E multiple on updated 2025 EPS.
Pfizer&#8217;s stock is trading at a price-to-earnings ratio of about 8–9 times its expected 2025 earnings. That&#8217;s lower than the peer average of around 12 times, excluding Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
It also offers a high dividend yield of around 7%, which may help prevent the share price from falling further. However, the long-term outlook is less certain due to upcoming patent expirations and increased competition, which could result in slower-than-average growth.
Pfizer expects its 2025 sales to decline by about $1 billion due to changes under the Inflation Reduction Act (IRA) Part D reform. The company anticipates a $500 million increase in revenue from more patients using its drugs, thanks to lower out-of-pocket costs. However, this is offset by a $1.5 billion loss due to increased costs in the catastrophic phase of Medicare Part D.
Cheaper options (i.e. Eliquis) may benefit from certain reforms more than expensive drugs because the coverage gap is being removed.
In the first quarter of 2025, Pfizer says it already felt a negative impact of around $650 million compared to the same period in 2024, due to higher discount requirements for drugmakers.
Price Action: PFE stock is down 0.64% at $25.49 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46396808/wolfspeed-wolf-stock-resumes-rally-amid-restructuring-optimism" target="_blank" rel="noreferrer noopener">Wolfspeed (WOLF) Stock Resumes Rally Amid Restructuring Optimism</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

General

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook

Citigroup analyst Andrew Kaplowitz maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Buy and raises the price target from $445 to $502.

Price Target

Citigroup Maintains Buy on Trane Technologies, Raises Price Target to $502

<a href="https://www.bloomberg.com/news/articles/2025-07-14/andrew-cuomo-plans-to-stay-in-nyc-mayoral-race-as-independent?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-14/andrew-cuomo-plans-to-stay-in-nyc-mayoral-race-as-independent?embedded-checkout=true</a>

Politics

'Andrew Cuomo Plans to Stay in NYC Mayoral Race as Independent'- Bloomberg

<a href="https://www.nytimes.com/2025/07/14/technology/meta-superintelligence-lab-ai.html">https://www.nytimes.com/2025/07/14/technology/meta-superintelligence-lab-ai.html</a>

'Meta's New Superintelligence Lab Is Discussing Major A.I. Strategy Changes'- New York Times

Citigroup analyst Andrew Kaplowitz maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and raises the price target from $371 to $392.

Citigroup Maintains Buy on Rockwell Automation, Raises Price Target to $392

Citigroup analyst Andrew Kaplowitz maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Buy and raises the price target from $99 to $125.

Citigroup Maintains Buy on Pentair, Raises Price Target to $125

Autodesk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) shares are trading higher Monday after the company officially announced it will no longer pursue the<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46350878/autodesk-adsk-shares-slide-amid-reports-of-potential-ptc-acquisition"> acquisition of PTC Inc</a>.
What To Know: The move comes after weeks of speculation following reports that Autodesk was considering a major cash-and-stock deal for the industrial software firm. Investors reacted positively to the decision, reversing some of the pressure that had weighed on Autodesk stock since the initial reports surfaced.
Shares of Autodesk had fallen over 10% since July 8, the day before <a href="https://www.bloomberg.com/news/articles/2025-07-14/autodesk-is-said-to-drop-pursuit-of-software-firm-ptc?srnd=technology-ai&amp;embedded-checkout=true">Bloomberg </a>reported that the company was exploring a potential acquisition of PTC. The proposed deal would have ranked among the largest in the software sector this year, potentially reshaping Autodesk&#8217;s strategic direction. On Friday, Autodesk shares closed at $280.39, giving the company a market value of around $60 billion. PTC's market capitalization stands at roughly $23.2 billion.
In a regulatory filing on Monday, Autodesk confirmed that it would remain focused on its existing strategic priorities. These include investing in its core business, pursuing smaller targeted acquisitions, and continuing its share repurchase program. The company made no mention of PTC or any other acquisition targets in the filing, signaling that it intends to stick with its organic growth plans rather than pursuing large-scale deals.
PTC, founded in the 1980s, specializes in software that supports manufacturers in designing complex products such as aircraft, electronics, and medical devices. A deal between Autodesk and PTC would have marked a significant consolidation in the industrial software space, a sector expected to grow with the rising adoption of artificial intelligence. However, Autodesk's decision to walk away suggests that the company is opting to prioritize financial discipline and shareholder returns over high-risk acquisitions.
ADSK Price Action: Autodesk shares were up 5.50% at $295.82 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46397545/nvidias-jensen-huang-china-doesnt-need-us-chips">Nvidia&#8217;s Jensen Huang: China Doesn&#8217;t Need US Chips</a></li>
</ul>
Image Via Shutterstock.

Movers

ADSK

What's Going On With Autodesk Shares Today?

Citigroup analyst Andrew Kaplowitz maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Buy and raises the price target from $709 to $831.

Citigroup Maintains Buy on Parker Hannifin, Raises Price Target to $831

Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares are trading higher Monday on possible continued momentum after Secretary of Defense Pete Hegseth announced efforts to fast <a href="https://www.benzinga.com/node/46372724">track drone production.</a>
What To Know: On Thursday, Hegseth issued a directive allowing military commanders at the rank of colonel or Navy captain and above to independently purchase and test small drones—specifically Group 1 and 2 unmanned aircraft systems.
Furthermore, the order reclassifies these drones as "consumable weapons," removing them from traditional aircraft tracking systems and accelerating the deployment of emerging tech, including 3D-printed and off-the-shelf models.
The directive also rolls back several outdated Pentagon policies that Hegseth said were stalling innovation. It requires all military branches to conduct drone combat simulations and coordinate with the FAA to expand flight ranges, fast-track spectrum approvals and create new testing zones for swarm tactics, live-fire drills and joint-force exercises.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46399600/nebius-emerges-as-neutral-ai-cloud-alternative-deepens-ties-with-nvidia-openai-microsoft-analyst">Nebius Emerges As Neutral AI Cloud Alternative, Deepens Ties With Nvidia, OpenAI, Microsoft: Analyst</a>
RCAT Price Action: At the time of writing, Red Cat stock is trading 15.7% higher at $9.91, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image via Shutterstock

RCAT

Red Cat Stock Is Moving Higher Monday: What's Going On?

Citigroup analyst Vladimir Bystricky maintains nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) with a Buy and raises the price target from $69 to $86.

Citigroup Maintains Buy on nVent Electric, Raises Price Target to $86

<a href="https://www.bloomberg.com/news/articles/2025-07-14/us-bank-regulators-provide-blueprint-for-lenders-crypto-custody">https://www.bloomberg.com/news/articles/2025-07-14/us-bank-regulators-provide-blueprint-for-lenders-crypto-custody</a>

'US Bank Regulators Provide Blueprint for Lenders' Crypto Custody'- Bloomberg

Citigroup analyst Andrew Kaplowitz maintains Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) with a Buy and raises the price target from $23 to $24.

Citigroup Maintains Buy on Mirion Technologies, Raises Price Target to $24

Citigroup analyst Andrew Kaplowitz maintains Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) with a Buy and raises the price target from $17 to $21.

Citigroup Maintains Buy on Mayville Engineering, Raises Price Target to $21

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) on Monday announced it has added another 4,225 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its already dominant crypto treasury, spending approximately $472.5 million at an <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46397477/bitcoins-123k-boom-meets-crypto-week-blastoff-moment-for-microstrategy-marathon-digital">average price of $111,827 per coin</a>.
The purchase was disclosed Monday morning in a Form 8-K <a href="https://assets.contentstack.io/v3/assets/bltf8d808d9b8cebd37/blt4cc1a0ae496ac9e3/68747439e8921d53d6fa6b41/form-8-k_07-14-2025.pdf">filing</a> with the U.S. Securities and Exchange Commission.
The acquisition pushes Strategy's total holdings to 601,550 BTC, acquired for roughly $42.87 billion at an average price of $71,268 per Bitcoin. 
The announcement comes amid Bitcoin's recent surge past $122,000, underscoring Strategy's aggressive buy-the-dip approach that now spans across more than three years and multiple bull-bear cycles.
What makes this purchase noteworthy isn't just the size, but the source of the funds: Strategy financed the latest acquisition using proceeds from four concurrent at-the-market (ATM) equity offerings, including its common stock and three series of preferred shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRK#NASDAQ">STRK</a>), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>) and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRD#NASDAQ">STRD</a>).
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46394828/bitcoin-eth-xrp-solana-are-in-for-a-long-and-exhausting-bull-market-bernstein-predicts">Bitcoin, ETH, XRP, Solana Are In For A &#8216;Long And Exhausting Bull Market,&#8217; Bernstein Predicts</a>
Over the same week, the company raised more than $472 million through those offerings, converting equity capital directly into Bitcoin with little delay.
The company's strategy, blending traditional capital markets with direct Bitcoin accumulation, continues to test conventional corporate treasury management. 
While the firm has become a proxy for institutional Bitcoin exposure on Wall Street, its risk posture remains polarizing. 
Critics warn of overexposure and limited liquidity, while supporters view the firm as an early archetype for how public companies can integrate digital assets into their balance sheets at scale.
Strategy's public dashboard indicates the company has now purchased more than 13,000 BTC in July alone, suggesting that the current accumulation cycle is far from over, even as Bitcoin trades at all-time highs.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46392541/how-donald-trumps-big-beautiful-bill-was-a-big-beautiful-boost-for-bitcoin">How Donald Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Was A &#8216;Big Beautiful Boost&#8217; For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

STRD

STRF

STRK

Strategy Adds $472 Million In Bitcoin, Ups Total Holdings To Over 600,000 BTC

Citigroup analyst Andrew Kaplowitz maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Neutral and raises the price target from $94 to $110.

Citigroup Maintains Neutral on Johnson Controls Intl, Raises Price Target to $110

As silver prices reach levels not seen in <a href="https://www.benzinga.com/markets/market-summary/25/07/46374536/wall-street-today-trump-eu-tariffs-gold-rallies-silver-bitcoin" target="_blank" rel="noopener">almost 14 years</a>, investors are not only stocking up on bars, but they&#8217;re also loading up on silver ETFs at a record pace. And the game is no longer about price momentum. Structural changes in demand, constricting physical supply, and gold&#8217;s rapidly unaffordable glamour are pointing capital toward <a href="https://www.benzinga.com/etfs">ETFs linked to silver</a>, the &#8220;poor man&#8217;s gold&#8221; that&#8217;s now enjoying a rich run.
Silver ETFs added more than 2,570 tons of the metal since February, Bloomberg data shows, and they are playing a central role in the most recent supply squeeze. The effect has been so sharp that it&#8217;s now tightening the physical silver market in London, the main vaulting center for ETF holdings, and driving borrowing rates for the metal to more than 6%, an astonishing spike from their typical near-zero level.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/07/46305133/central-banks-provide-gold-tailwinds-silver-gains-traction-platinum-pauses">Central Banks Provide Gold Tailwinds, Silver Gains Traction, Platinum Pauses</a>
<h2 class="wp-block-heading">ETF Buyers At The Forefront</h2>
While <a href="https://www.benzinga.com/topic/silver">physical silver markets </a>are constrained, silver ETFs are the investment of choice for both retail and institutional investors seeking to enjoy the rally. Let&#8217;s see how the top players compare:
iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>)
The heavy hitter in the silver ETF space, SLV, holds over 474 million ounces of silver and manages nearly $18 billion in assets under management (AUM). It follows the price of silver by maintaining physical bullion in vaults, providing a low-friction means to get exposure without the hassles of storage.
Why it matters: The largest and most liquid silver ETF, SLV, frequently serves as a barometer of investor sentiment towards the metal. The fund is up almost 30% this year so far.
Aberdeen Standard Physical Silver Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIVR#NYSE">SIVR</a>)
SIVR follows essentially the same approach as SLV, owning fully allocated physical silver, but draws more budget-price-conscious investors. At an expense ratio of 0.30%, versus SLV&#8217;s 0.50%, it has slowly gained a niche.
Why it&#8217;s important: Lower costs become more appealing in a high-inflation world where even slight differences in interest rates matter. Like SLV, the fund is up 30% so far this year.
Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>)
Those who want silver exposure but prefer the equity approach can achieve it via SIL, which offers access to a portfolio of international silver mining firms, including Fresnillo (OTCPK: FNLPF), Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>), and Hecla Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>).
Why it matters: Although mining stocks provide leverage to silver prices, they also carry company-specific and geopolitical risks. SIL is rising sharply this year as silver miners benefit from the bull run. The fund is up a good 53.5% this year.
<h2 class="wp-block-heading">What&#8217;s Driving The Demand?</h2>
A variety of forces are driving investor demand:
Relative value: Silver remains trading below its historic ratio to gold. At an 86 gold-to-silver ratio, silver could be undervalued, given that the number averages nearer to 80 over the past decade.
Trade tensions: The most recent round of threats of tariffs between the U.S. and Mexico, the globe&#8217;s leading silver producer, raised concerns about potential supply interruptions.
Industrial demand: Silver is an essential input for solar panels and electronics, making it have a special dual identity, both a precious metal and an industrial commodity.
Supply deficit: The Silver Institute estimates a fifth straight year of market deficit in 2025, as cited by Bloomberg, further solidifying the long-term investment thesis.
<h2 class="wp-block-heading">The Bigger Picture For ETF Flows</h2>
This year&#8217;s rally has transformed silver ETFs from quiet portfolio diversifiers into high-conviction trades. While gold ETFs have mostly recorded flat to negative inflows due to high prices and risk-off central bank sentiment, silver ETFs are attracting new money, courtesy of their lower entry price and more compelling upside story.
If silver continues to outpace gold, as it has to date in 2025, the pace of ETF flows will gain even more momentum, particularly for retail investors seeking exposure without exceeding their budgets.
Silver does not have the bling of gold, perhaps, but in the world of ETFs, it&#8217;s stealing the spotlight right now. Tightening physical supply and increasing investor appetite have turned silver ETFs from supporting actors to protagonists in the commodity resurrection.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46398559/are-your-tesla-etfs-secretly-betting-on-elon-musks-ai-startup">Are Your Tesla ETFs Secretly Betting On Elon Musk's AI Startup?</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

FNLPF

PAAS

SIVR

Silver ETFs Just Crashed Gold's Party— And Took The Cake

Citigroup analyst Vladimir Bystricky maintains ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) with a Buy and raises the price target from $159 to $186.

Citigroup Maintains Buy on ITT, Raises Price Target to $186

Crinetics Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) on Sunday announced new data from its clinical development program evaluating once-daily, oral investigational palsonify (paltusotine) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in acromegaly</a>.
Acromegaly&nbsp;is a rare condition in adults that causes some bones, organs and other tissues to grow bigger.
The data will be presented at the Endocrine Society&#8217;s Annual Meeting, ENDO 2025.
Also Read: <a href="https://www.benzinga.com/25/03/44502320/jp-morgan-survey-90-of-endocrinologists-aware-of-crinetics-atumelnant-data" target="_blank" rel="noreferrer noopener">JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics&#8217; Atumelnant Data</a>
<h2 class="wp-block-heading">PATHFNDR-1 Open-Label Extension (OLE) Study</h2>
The PATHFNDR-1 Phase 3 trial enrolled adults with acromegaly who were biochemically controlled on monthly injectable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46383977/crinetics-to-present-new-long-term-data-demonstrating-durable-control-of-once-daily-oral-palsonify" rel="noreferrer noopener">somatostatin receptor ligands (SRLs)</a>.
Following a 36-week randomized, placebo-controlled period, 53 of 58 participants (91%) entered the ongoing single-arm open-label extension. An interim analysis includes data through week 96 of total study participation (60 weeks in the OLE).
In patients who transitioned from injected SRLs to once-daily oral palsonify, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and 0.81 ± 0.21 times the upper limit of normal (ULN) at week 96, demonstrating durable biochemical control over this period.
Growth hormone (GH) levels were also stable, with mean values of 1.0 ± 1.0 ng/mL at baseline and 1.1 ± 1.2 ng/mL at week 96.
Symptom control also remained stable at week 96.
<h2 class="wp-block-heading">PATHFNDR-2 OLE Study</h2>
The interim analysis includes efficacy data from 88 patients through week 84 (corresponding to 60 weeks in the OLE), with safety data reported for all 114 enrolled.
Patients who had received a placebo during the RC phase experienced sustained reductions in IGF-1, with a mean change from baseline of –0.81 × ULN at week 84 (n=39).
Direct-to-OLE participants (n=9) showed similar reductions (–0.75 × ULN), while those who had been treated with palsonify during the RC phase (n=40) maintained control (mean change –0.01 × ULN).
Growth hormone, symptom scores, and pituitary tumor size were durably controlled over the study period.
In both trials, palsonify was well-tolerated.
A pooled analysis of symptom scores from PATHFNDR-1 and PATHFNDR-2 showed that greater proportions of patients treated with palsonify experienced less acromegaly symptom burden compared to placebo, regardless of the magnitude of the symptom effect, treatment history or state of biochemical disease control.
In an analysis of PATHFNDR-1 data, biochemically controlled patients switching from injected SRLs to palsonify saw a significant drop in day-to-day symptom exacerbations, from over 30% of days on SRLs to just 6.2% during stable palsonify dosing.
CRNX Price Action: Crinetics Pharmaceuticals stock is up 3.07% at $32.91 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46386533/dave-ramsey-warns-bankruptcy-is-huge-red-flag-that-can-delay-homeownership-by-years" target="_blank" rel="noreferrer noopener">Dave Ramsey Warns Bankruptcy Is &#8216;Huge Red Flag&#8217; That Can Delay Homeownership By Years</a></li>
</ul>
Photo: Gorodenkoff via Shutterstock

CRNX

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) from Outperform to Market Perform.

Downgrades

INKT

William Blair Downgrades MiNK Therapeutics to Market Perform

Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). 
The drug targets post-bariatric hypoglycemia (PBH), a condition marked by dangerously low blood sugar following weight-loss surgery.
In the Phase 2b trial, a 90 mg once-daily dose of avexitide—now being evaluated in the Phase 3 LUCIDITY trial—achieved a 64% reduction in the rate of moderate to severe hypoglycemic events. More than half of participants experienced no such events during treatment.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46081532/amylyx-eyes-2b-opportunity-in-post-surgery-sugar-crash-market" target="_blank" rel="noreferrer noopener">Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market</a>
LUCIDITY, a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial, is evaluating the safety and efficacy of avexitide in approximately 75 patients with PBH following Roux-en-Y gastric bypass surgery. The FDA-designated primary endpoint is a reduction in Level 2 and 3 hypoglycemic events.
Previous trials, including Phase 2 PREVENT and Phase 2b, showed consistent, dose-dependent reductions in these events across multiple dosing regimens. Notably, the 90 mg once-daily dose demonstrated sustained 24-hour GLP-1 receptor inhibition, supported by pharmacokinetic and pharmacodynamic data presented at ENDO 2025. In vitro studies confirmed potent target engagement, with avexitide plasma levels exceeding the IC₅₀ threshold throughout the dosing window.
Across five clinical trials, avexitide has shown statistically and clinically meaningful efficacy with a favorable safety profile. LUCIDITY is expected to complete enrollment in 2025, with top-line results anticipated in the first half of 2026 and a potential commercial launch in 2027.
Price Action: AMLX stock is up 7.55% at $8.26 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025" target="_blank" rel="noreferrer noopener">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Image: Shutterstock

Trading Ideas

Amplify YieldShares Oil Hedged MLP Income ETF

Comments

Everbright Digital Hldgs

Everbright Digital Hldgs (EDHL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL